Review Article

Aidi Injection as Adjuvant Drug Combined with Chemotherapy in Treatment of Breast Cancer: A Systematic Meta-Analysis

Chenhao Wu (b),¹ Yongjun Qi (b),² Juan Zhou (b),² Chen Yao (b),² Min Miao (b),² and Chen Cheng (b)²

¹Breast Surgery Department, Hainan Women and Children's Medical Center, No. 75 Longkun Nan Road, Hai Kou, Hainan Province, China

²Obstetrics and Gynecology Department, Jiangdu People's Hospital of Yangzhou, No. 9 Dongfang Hong Road, Jiangdu District, Yangzhou, Jiangsu Province, China

Correspondence should be addressed to Chen Cheng; chengsisi996@163.com

Received 2 September 2020; Revised 2 November 2020; Accepted 11 December 2020; Published 8 January 2021

Academic Editor: Azis Saifudin

Copyright © 2021 Chenhao Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To compare the efficacy and safety of combination of Aidi injection and chemotherapy and chemotherapy alone in treatment of breast cancer. *Methods.* The related control and randomized studies till August 1st, 2020, were retrieved in the database including PubMed, Embase, Cochrane Library, CNKI, CBM, Wang-Fang, and VIP. Primary outcomes were response rate (RR) and performance status (KPS) improvement rate; secondary outcomes were rate of adverse drug reactions (ADR) including myelosuppression, digestive tract reaction, liver dysfunction, and cardiac toxicity. Review Manager 5.3 was used in the present analysis. *Results.* In total, 20 studies (18 articles) were included in the present analysis. RR (OR 1.76 (1.32, 2.35); p = 0.0001) and KPS improvement rate (OR: 2.68 (1.34, 6.46); p = 0.007) in Aidi injection plus chemotherapy group were significantly higher than those of chemotherapy alone group. Addition of Aidi injection significantly reduced the rate of myelosuppression, digestive tract reaction, leukocyte decrease, II-IV cardiac function abnormality, atrial dysrhythmia, ventricular arrhythmia, ST segment T wave inversion, and abnormal ECG (all p < 0.05). *Conclusion.* Aidi injection could increase the efficacy of chemotherapy, could reduce myelosuppression, digestive tract reaction, and cardiac toxicity induced by chemotherapy, and did not lead to additional toxicity and side effect. Therefore, it is an anticancer drug with good efficacy and low toxicity, worth further popularization.

1. Introduction

Breast cancer is a common cancer type and is the fifth most common cause of cancer death [1]. In 2012, there were 1.67 million newly diagnosed breast cancer cases, comprising 25% of all sorts of cancers among females [2]. In China, the number of breast cancer cases increased dramatically. The number of newly diagnosed breast cancer cases in 2000 was 121,2693, and this number reached 168,013 in 2005 [3], and 278900 in 2014 [4]. The main options in breast cancer treatment included surgery, chemotherapy, and radiation. Among them, chemotherapy has been a widely accepted and applied treatment method. However, chemotherapy usually temporarily relieves symptoms, lengthens survival, but occasionally cures the disease, so its treatment efficacy is still to be improved [5]. On the other hand, the related toxicity greatly affected quality of life of patients. Therefore, much work has been made to find alternative treatment methods. In recent years, Traditional Chinese Medicine (TCM) received much attention in the field of cancer treatment due to its capability of efficacy improvement and toxicity reduction [6].

Aidi injection was one of the Chinese Patent Medicines with anticancer acitivity included in Catalogue of Drugs for Basic National Medical Insurance and Countermeasures of China [7]. It is extracted from Chinese herbal medicines of catharides, ginseng, astragalus, and acanthopanax senticosus. In opinion of TCM, Aidi injection has the ability of clearing away heat and toxin, removing stasis, and dispersing accumulation. Cantharidin is the major component for toxicity of cantharides and also is an effective anticancer component. It can inhibit cancer cells without decreasing the pericirculation leucocytes level and has obvious immune-suppression effect, which is quite outstanding for current anticancer drugs [8]. Ginseng, astragalus, and acanthopanax senticosus have showed anticancer capability of inducing apoptosis of cancer cells, inhibiting proliferation of cancer cells, inhibiting cancerous angiogenesis, and so on, and they usually also have features of low toxicity, low drug resistance, and obvious immune-improvement capability. In China, Aidi injection was extensively used in the treatment of primary liver cancer [9], lung cancer [10], gastric cancer [11], colon cancer [12], lymphadenoma [13], gynecology cancer [14], and so on. In clinical practice, Aidi injection is usually used as adjuvant drug in chemotherapy in cancer treatment to decrease toxicity of chemotherapy and improve quality of life [15]. There have been a number of clinical studies investigating combination of Aidi injection with chemotherapy in cancer treatment. In the studies among breast cancer patients, addition of Aidi injection had showed certain benefits. Therefore, we performed this meta-analysis to systematically review and evaluate the efficacy and safety of Aidi injection as adjuvant drug in chemotherapy in the treatment of breast cancer.

2. Materials and Methods

2.1. Inclusion and Exclusion Criteria. The inclusion criteria were as follows: (1) types of studies: randomized controlled trials; retrospective or observational studies were not eligible; (2) types of participants: pathologically or cytologically diagnosed with breast cancer; Karnofsky performance status score ≥ 60 ; (3) intervention: patients in control group received pure chemotherapy and the patients in the experimental group received chemotherapy plus Aidi injection; (4) outcome measurements: at least one of the three measurements was evaluated: short-term response rate for solid tumor, performance status improvement rate, and adverse events rate.

Exclusion criteria were as follows: (1) other Traditional Chinese Medicines were used during study period; (2) other cancer treatments such as radiation therapy or immunological or target treatment were used during study period.

2.2. Retrieval Strategy. We searched the related studies till August 1st, 2020, using the database including PubMed, Cochrane library, Embase, and Chinese medical databases: CNKI, CBM, Wang-Fang, and VIP. The retrieval terms were "Aidi injection" or "Aidi", AND "breast cancer", OR "breast tumor" OR "breast carcinoma" in retrieval using PubMed, Cochrane library, and Embase. These terms in English and Chinese both were used for CNKI, CBM, Wang-Fang, and VIP. The references of important articles were also searched. 2.3. Literature Screening, Data Extraction, and Quality Assessment. Two independent reviewers (WCH and QY) made the literature screening and data extraction, respectively. For each literature screening, duplication, title, abstract, and main text were examined. The screening results by the two reviewers were compared and decided through discussion. When agreement could not be made with discussion, a third independent reviewer (YC) was invited to make final decision. The extracted information included author name, publication year, sample size, TNM stage, intervention methods, treatment cycles, and outcome measurements.

Quality assessments were made with Cochrane risk of bias tool as suggested by Cochrane handbook for systematic reviews of interventions. The assessed measurements include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. Each measurement was rated with low, unclear, and high bias risk.

2.4. Outcome Measurements. Short-term treatment efficacy was determined according to the modified Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1) [16]. Response rate = number of patients with complete response + number of patients with partial response rate/ total patient number. Performance status was assessed with Karnofsky Performance Status (KPS) score. After treatment, increase of KPS score from baseline ≥ 10 was considered as KPS improvement; decrease of KPS score from baseline ≥ 10 was considered as KPS reduction; KPS score above or below <10 was considered as stable KPS. KPS improvement rate = number of patients with KPS improvement/total patient number. The toxicity and adverse events were assessed as I°, II°, III°, and IV°, according to the common toxicity criteria of chemotherapy drugs drafted by WHO (1991); cardiac function abnormality was also assessed according to the WHO anticancer drug toxicity criteria. Grade 0 indicates that heart rate, rhythm, and function are normal; I°indicates no symptoms of cardiac insufficiency and may present abnormal cardiac signs; grade II° indicates transient cardiac insufficiency, no treatment needed; grade III° indicates presenting symptoms of cardiac function insufficiency which are manageable; IV° indicates presenting symptoms of cardiac function insufficiency which are unmanageable.

2.5. Statistical Analysis. Review Manager 5.3 was used for meta-analysis. Odds ratios (OR) for categorial or continuous variables of experimental group (Aidi injection plus chemotherapy) and control group (chemotherapy alone) were calculated and compared. P < 0.05 was considered to be statistically significant. The heterogeneity between the included studies was tested with the standard Chi-squared (I^2 Q) test. If p < 0.1, $I^2 < 50\%$, fixed effect model was used for analysis; if p < 0.1, $I^2 > 50\%$, random effect model was used. Subgroup analyses according to number of cycles (≤ 3 vs >3) were made to identify the heterogeneity source. Funnel plot

was used for estimation of publication bias. If the number of included studies was less than 10, publication bias was not assessed.

3. Results

3.1. Literature Screening Results and Characteristics of the Included Studies. Following the search strategy described above, 96 articles were retrieved. Among them, 23 were retrieved from CNKI, 26 were retrieved from CBM, 22 were retrieved from VIP, 24 were retrieved from Wan-Fang, 1 was retrieved from PubMed, 0 were retrieved from EMBASE, and 0 were retrieved from Cochrane library. After duplicate checking, 26 articles were obtained. After title and abstract examination, 3 articles were excluded. After main-text examination, 5 articles were excluded: 1 study did not evaluate the measurements of response rate or performance status improvement rate; 1 study did not provide TNM stage of included patients; 1 study was single arm study rather than randomized controlled study; 1 study was performed among patients with cancer other than breast cancer; 1 study used TCMs other than Aidi injection. Finally, 18 articles (20 studies) were included in the present meta-analysis. The flowchart of article selection process is shown as Figure 1.

The characteristics of the 20 included studies are shown in Table 1 [17-34]. All the 20 studies were published in Chinese journals. The study performed by Gao et al. compared Aidi plus chemotherapy and chemotherapy alone, respectively, among treatment naïve patients and patients with drug resistance for anthracycline and paclitaxel, so the two comparisons were both included and regarded as two studies: Gao QH 2013a and Gao QH 2013b [21]. The study performed by Wang GD et al. compared low-dose Aidi plus chemotherapy and high-dose Aidi plus chemotherapy and chemotherapy alone, so two comparisons (low dose vs control; high dose vs control) were included and regarded as two studies: Wang GD 2012a and Wang GD 2012b [30]. The patients in four studies performed by Chen WM et al. [17], Han et al. [22], Wang GD et al. [30], and Jin et al. [23] received chemotherapy after surgery. The other studies out of the four studies did not administrate surgery. The chemotherapies were regular regimen but varied among the studies. The dosage of Aidi injection ranged from 50 ml to 100 ml.

3.2. Quality Assessment Result. All the included studies were randomized controlled studies. The baseline characteristics of patients were well balanced between the experimental group and control group. Five studies reported the randomized sequence generation methods [19, 20, 25, 29, 32]; 5 studies had evaluated long-term efficacy so they reported follow-up [20, 27, 29, 31, 34] and the rest studies did not as they only evaluated short-term efficacy; 6 studies evaluated adverse events rate and reported multiple adverse events but did not provide overall data of all adverse events that

occurred [20, 21, 24, 26, 31] and the rest of studies had made complete reports of all or certain adverse events; 1 study reported drop-out rate [22]. However, in all the studies, the blindness of allocation and assessment was not described, so they were rated as unclear; the blindness of participants and personals was not described either and was rated as high risk based on the general practice in hospital of China (Figures 2 and 3).

3.3. Outcomes

3.3.1. Response Rate. 15 studies were included in the analysis of response rate, which included 970 patients, 508 in Aidi plus chemotherapy group and 462 in chemotherapy alone group (Figure 4). The heterogeneity between the included studies was not significant (p = 0.92; $I^2 = 0\%$), so fixed-effect model was used. The analysis results indicated that the pooled response rate in Aidi plus chemotherapy group was significantly higher than that of the chemotherapy alone group (OR 1.76 (1.32, 2.35); p = 0.0001). Funnel plot was adopted to estimate the publication bias and the result suggested no obvious publication bias (Figure 5).

3.3.2. Performance Status Improvement Rate. Eight studies were included in the analysis of performance status improvement rate, which included 700 patients, 345 in Aidi plus chemotherapy group and 355 in chemotherapy alone group (Figure 6). Heterogeneity between the included studies was significant (p = 0.03, $I^2 = 54\%$), so random-effects model was used. The analysis result showed that performance status improvement rate in the patients receiving Aidi plus chemotherapy was significantly higher than that in the patients receiving chemotherapy alone (OR: 2.68 (1.34, 6.46); p = 0.007).

However, in subgroup analysis in respect to cycle numbers, the difference of performance status improvement rate was significant in the subgroup in which chemotherapy cycles were >3 (OR: 12.42 (4.56, 33.85); p < 0.00001), and heterogeneity was not significant (p = 0.95, $I^2 = 0\%$) (Figure 7); the performance status improvement rate was not significantly different in the subgroup in which chemotherapy cycles were ≤ 3 (OR: 1.66 (0.95, 2.89); p = 0.07), and the heterogeneity was not significant between the studies (p = 0.51, $I^2 = 0\%$) (Figure 7). Furthermore, the heterogeneity between the two subgroups was significant (p = 0.0006; $I^2 = 91.6\%$) (Figure 7), indicating that chemotherapy cycles >3 or ≤ 3 were a source of heterogeneity in the total analysis.

Again, subgroup analysis regarding Aidi injection of high (100 mL) or low (50 mL) dose was also performed (Figure 8) to determine the source of heterogeneity. In the subgroup of low-dose Aidi, heterogeneity was not significant (p = 0.38, $I^2 = 1\%$). The pooled performance improvement rate was significantly higher in low-dose Aidi plus



FIGURE 1: Flowchart of the studies selection process.

chemotherapy group [OR: 2.11 (1.12, 3.99); p = 0.02]. In the subgroup of high-dose Aidi, the heterogeneity between studies was significant (p = 0.01, $I^2 = 73\%$); the pooled performance improvement rate was not significantly different in this subgroup analysis [OR: 3.48 (0.70, 17.36); p = 0.13] (Figure 8). However, the difference between the subgroups was not significant (p = 0.57, $I^2 = 0\%$).

3.4. Adverse Drug Events Rate

Myelosuppression Rate. Seven studies were included in the analysis for myelosuppression rate, which included 486 patients, 246 in Aidi injection plus chemotherapy group and 240 in chemotherapy group (Figure 9). The heterogeneity between the included studies was not significant (p = 0.8, $I^2 = 0\%$). The analysis result indicated that the pooled myelosuppression rate of Aidi plus chemotherapy group was significantly lower than that of the chemotherapy alone group (OR: 0.34 (0.20, 0.55); p < 0.0001).

Furthermore, 4 studies were included in the analysis for III-IV grade myelosuppression rate. Heterogeneity was not significant (p = 0.25%, $I^2 = 28\%$) (Table 2). The pooled III-IV grade myelosuppression rate was significantly lower in Aidi plus chemotherapy group (OR: 0.43 (0.25, 0.76); p = 0.03) (Table 2).

Digestive Tract Reaction Rate. Eight studies were included in the analysis for digestive tract reaction rate, which included 623 patients (Figure 10). The heterogeneity between studies was not significant (p = 0.72, $I^2 = 0\%$). The analysis result indicated that the pooled digestive tract reaction rate was significantly lower in Aidi plus chemotherapy group, when compared with chemotherapy alone group (OR: 0.50 (0.17, 1.47); p = 0.001).

The analysis for III-IV grade digestive tract reaction rate included 4 studies (Table 2). The heterogeneity was shown between studies (p = 0.06; $I^2 = 59\%$). The III-IV grade digestive tract reaction rate was significantly lower in Aidi plus chemotherapy group (OR: 0.42 (0.22, 0.80); p = 0.008).

Other ADRs. The other adverse drug reaction rates were also compared, as shown in Table 2. The pooled total and II-IV grade leukocyte decrease rate were shown to be significantly lower in Aidi plus chemotherapy group (both p < 0.05). The adverse events rates related to cardiac toxicity, including II-IV cardiac function abnormality, atrial dysrhythmia, ventricular arrhythmia, ST segment T wave inversion, and abnormal ECG, were significantly lower in Aidi plus chemotherapy group (all p < 0.05). The total and III-IV grade liver dysfunction rate, total and III-IV hair loss rate, phlebitis rate, and atrioventricular block rate were not significantly different between the two groups (all p < 0.05).

studies.
included
of
Characteristics
÷
TABLE

Dinot anthon	V age	No.	Λ ~~ Λ	0.4000		Intervention	
FIIST AULIUI	ıcaı	E/C	Age	olage	ourger)	Control group	Experimental group
Eisenhauer [16]	2016	40/39	$46.73 \pm 14.29/$ 45.98 ± 15.78	III-IVa	Yes	CEF (6 cycles): CTX 600 mg/m ² , d1, 8; EPI 100 mg/m ² , d1; 5-FU 500 mg/m ² , d1, 8; 21d	CT + Aidi 100 ml, qd, d1-8
Chen [17]	2012	30/26	42.5/42.5	III-II	No	AC-T (3 courses): ADM 60 mg/m ² , d1+CTX 600 mg/m ² , d1; 14d, for 4 cycles; followed by TAX 175 mg/m ² , d1, 14d, 4 cycles	CT + Aidi 100 ml, qd, 4d
Chen [18]	2010	28/20	36.2/37.5	I-IIIa	No	CTF (3 cycles): CTX 400–600 mg/m ² , 5-Fu 400–600 mg/m ² , d1, 8; THP 40–50 mg/m ² , d1, 21d	CT + Aidi 100 ml, qd, 10d
Fu [19]	2007	44/44	42/48	IV	No	NP (above 2 cycles):NVB 25 mg/m ² , d1, 8; DDP 30 mg/m ² , d2-4; 28d	CT + Aidi 50 ml, qd, d 1-15
Dang [20]	2014	64/64	46.7 ± 20.3	Not clear	Yes	CEF (6 cycles): CTX 600 mg/m ² , d1, 8; EPI 100 mg/m ² , d1; 5-FU 500 mg/m ² , d1, 8; 21d	CT + Aidi 100 ml, qd, d1-8
Gao [21]	2013a	32/32	33–69	VI-III	No	TAC (at least 2 cycles): TXT 75 mg/m ² , d1; EPI 90 mg/m ² , d1; CTX 500 mg/m ² , d1; 21d	CT + Aidi 80 ml, qd, d1- 15
Gao [21]	2013b	16/16	33–69	VI-III	No	GEM + CAPE (at least 2 cycles) : GEM 1 g/m ² , d1, d8; CAPE 1 g/m ² , bid, d1-14; 21d	CT + Aidi 80 ml, qd, d1 - 15
Han [22]	2016	60/60	$53.9 \pm 11.5/$ 54.2 ± 12.1	Not clear	Yes	CAF/CEF/TAC (6 cycles)	CT + Aidi 100 ml, qd
Jin [23]	2005	50/50	45	III-II	No	CEF (2 cycles): CTX 600 mg/m ² , d1, 8; EPI 75 mg/m ² , d1; 5-FUDR 750 mg, d1, 8; 21d	CT + Aidi 100 ml, qd, d1-15
Liu [24]	2006	32/20	$46.2 \pm 2.6/44.5 \pm 3.2$	I-IIIa	No	CEF (3 cycles): CTX 400–600 mg/m ² , 5-FU 400–600 mg/m ² , d1, 8; EPI 75–90 mg/m ² , d1; 21d	CT + Aidi 100 ml, qd, 10d
Li [25]	2012	24/28	57.2 ± 3.5/55.7 ± 3.4	III-dII	No	TAC (2 cycles): TXT 75 mg/m ² , d1; EPI 100 mg/m ² , d1; CTX 600 mg/m ² , d1; 21d	CT + Aidi 80 ml, qd, d1- 15
Lu [26]	2005	60/40	39.5 (20-68)	III-II	No	CMF (3 cycles): CTX 600 mg/m ² , d1, 8; MTX 30 mg/m ² , d1; 5Fu 500 mg/m ² , d1, 8; 21d	CT + Aidi 80 ml, qd, d1- 15
Ren [27]	2013	26/22	42.3/42.2	III-II	No	TC-P (3 courses): THP 60 mg/m ² , d1, CTX 600 mg/m ² d1, 14 d/cycle, for 4 cycles; followed by TAX 175 mg/m ² , d1, 14d, 4 cycles	CT + Aidi 100 ml qd, 4d
Shen [28]	2006	48/48	51/50	IV	No	CAF or TA (2 cycles): CAF : CTX 600 mg/m ² , d1, THP 40 mg/m ² , d1; 5-FU 750 mg, d1, d8, 21d. TA : Taxol 135 mg/m ² , d1; THP 40 mg/m ² , d1; 21d	CT + Aidi 50 ml d1-15
Song [29]	2012a	38/41	$53.28 \pm 11.32/$ 53.02 ± 11.37	Not clear	Yes	CAF/CEF/AC/AT/TAC (6 cycles)	CT + Aidi 50 ml, qd
Song [29]	2012b	32/41	$52.67 \pm 11.85/$ 53.02 ± 11.37	Not clear	Yes	CAF/CEF/AC/AT/TAC (6 cycles)	CT + Aidi 100 ml, qd
Wang [30]	2016	21/21	46.5 (33–67)	IV	No	NP (at least 2 cycles): NVB 25 mg/m ² , d1, d8; DDP 30 mg/m ² , d2, 4; 28d	CT + Aidi 50 ml, qd, d1- 15
Wang [31]	2004	31/28	53.5 (31–70)/54.2 (32–69)	IV	No	NT (at least 2 cycles): NVB 25 mg/m ² , d1, 8; THP 40–50 mg/m ² , d1; 21	CT + Aidi 50 mg, qd, d1-15; 21d
Yang [32]	2005	30/30	48.4 (31–67)/47.6 (30–65)	VI-III	No	CAF (2 cycles): CTX 600 mg/m ² , d1, 8; ADM 50 mg/m ² , d1; 5-FU 500 mg/m ² , d1, 8; 21d	CT + Aidi 100 ml, qd, d1-10
Yang [33]	2016	36/37	53 (41–67)/54 (38–69)	VI-III	No	TXT + CAPE (6 cycles): TXT 75 mg/m ² , d1; CAPE 900 mg/m ² , bid, d1-14; 21d	CT + Aidi 100 ml, d1-14
CT = chemother ADM = adriamy were among the	apy; E/C cin; THP patients	= experim = pirarub failed in	icin; TXT = docetaxel; 5-F treatment with anthracyc	ap; 5-FU = TUDR = flo	= 5-fluoro xuridin; vaclitaxel.	uracil; TAX = paclitaxel; NVB = vinnorelbine; DDP = cisplatin; ADM = adriamycin; CTX = cyclopho: GEM = gemcitabine; CAPE = capecitabine. * Gao Qinghua 2013a were among the treatment-native pr	sphamide; EPI = epirubicin; atients; Gao Qinghua 2013b

Evidence-Based Complementary and Alternative Medicine



FIGURE 2: Risk of bias graph of included studies.

?	?	?	0	?	?	?	?	?	0	?	•	?	+	0	0	0	?	?	?	Selective reporting (reporting bias)
+	•	+	?	+	+	+	•	•	?	+	?	Ŧ	+	?	?	Ŧ	+	+	Ŧ	Incomplete outcome data (attrition bias)
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Blinding of outcome assessment (detection bias)
•		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	Blinding of participants and personnel (performance
?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	?	Allocation concealment (selection bias)
?	?	+	?	?	?	+	?	?	?	+	?	?	?	?	?	+	+	?	?	Random sequence generation (selection bias)
Zhang J 2016	Yang WJ 2005	Yang L 2004	Wang J 2016	Wang GD 2012	Wang GD 2012	Song WG 2006	Shen SD 2013	Ren ZG 2005	Lu CH 2012	Li XQ 2006	Liu ZZ 2005	Jin CG 2016	Han YH 2014	Gao QH 2013b	Gao QH 2013a	Fu L 2007	Dang XG 2010	Chen ZR 2012	Chen WM 2016	

FIGURE 3: Summary of risk bias of included studies.

Study or subgroup	Experi	nental	Cor	ntrol	Weight	Odds ratio		Odds	ratio	
Study of subgroup	Events	Total	Events	Total	(%)	M-H, fixed, 95% C	Ι	M-H, fixe	d, 95% CI	
Cheng ZR 2012	26	30	18	26	3.7	2.89 (0.75, 11.06)		_		
Dang XG 2010	26	28	18	20	2.2	1.44 (0.19, 11.22)			-	
Fu L 2007	26	44	27	44	16.0	0.91 (0.39, 2.14)				
Gao QH 2013a	23	32	18	32	7.3	1.99 (0.70, 5.62)		_		
Gao QH 2013b	8	16	7	16	5.1	1.29 (0.32, 5.17)				
Li XQ 2006	29	32	15	20	2.5	3.22 (0.68, 15.35)		_		
Liu ZZ 2005	35	50	32	50	13.9	1.31 (0.57, 3.03)				
Lu CH 2012	18	24	20	28	6.7	1.20 (0.35, 4.13)				
Ren ZG 2005	56	60	35	40	4.1	2.00 (0.50, 7.96)				
Shen SD 2013	22	26	15	22	3.6	2.57 (0.64, 10.33)		_		
Song WG 2006	32	48	22	48	10.6	2.36 (1.03, 5.40)				
Wang J 2016	19	21	17	21	2.3	2.24 (0.36, 13.78)				
Yang L 2004	22	31	19	28	8.4	1.16 (0.38, 3.51)				
Yang WJ 2005	23	30	15	30	5.1	3.29 (1.08, 9.95)				
Zhang J 2016	24	36	18	37	8.6	2.11 (0.82, 5.44)		-		
Total (95% CI)		508		462	100.0	1.76 (1.32, 2.35)			•	
Total events	389		296						Ŧ	
Heterogeneity: $chi^2 = 7$	7.30, d <i>f</i> = 14 (p = 0.92);	$I^2 = 0\%$				T		 	
Test for overall effect: 2	Z = 3.82 (p = 1)	0.0001)					0.01	0.1 1	10	100
								Favours (control)	Favours (experin	nental)

FIGURE 4: Forest plot of response rate in breast cancer patients receiving chemotherapy alone and chemotherapy plus Aidi injection.



FIGURE 5: Funnel plot of response rate for the publication bias.

Study or subgroup	Experi	mental	Cor	itrol	Weight	Odds ratio		Odds	ratio	
	Events	Total	Events	Total	(%)	M-H, random, 95% C		M-H, rando	m, 95% CI	
Yang WJ 2005	2	30	2	30	9.5	1.00 (0.13, 7.60)				
Liu ZZ 2005	5	50	5	50	15.0	1.00 (0.27, 3.69)				
Fu L 2007	15	44	13	44	19.2	1.23 (0.50, 3.03)			-	
Yang L 2004	17	31	8	28	17.2	3.04 (1.03, 8.96)		_		
Wang J 2016	19	21	15	21	11.4	3.80 (0.67, 21.60)		+		
Wang GD 2012a	3	38	0	41	5.4	8.18 (0.41, 163.85)				
Chen WM 2016	34	39	14	40	16.6	12.63 (4.03, 39.55)			_	
Wang GD 2012b	5	32	0	41	5.6	16.60 (0.88, 312.40)		+	•	
Total (95% CI)		285		295	100.0	2.94 (1.34, 6.46)			•	
Total events	100		57						-	
Heterogeneity: $tau^2 = 0.63$; $chi^2 = 15$		5.38, d <i>f</i> = 7	p = 0.03);	$I^2 = 54\%$			[1	
Test for overall effect: 2	Z = 2.68 (p = 1)	0.007)					0.001	0.1 1	10	1000
	1						Favour	s (experimental)	Favours (con	trol)

FIGURE 6: Forest plot of performance status improvement rate in patients receiving chemotherapy alone and chemotherapy plus Aidi injection.

Study or subgroup	Experimental Events Total		Con	trol	Weight	Odds ratio		Odd	s ratio	
Study of subgroup	Events	Total	Events	Total	(%)	M-H, random, 95% C	Ι	M-H, rand	om, 95% CI	
15.1.1 Chemotherapy c	ycles > 3									
Chen WM 2016	34	39	14	40	77.1	12.63 (4.03, 39.55)			— — — — — — — — — — — — — — — — — — —	
Wang GD 2012a	3	38	0	41	11.2	8.18 (0.41, 163.85)				
Wang GD 2012b	5	32	0	41	11.7	16.60 (0.88, 312.40)				
Subtotal (95% CI)		109		122	100.0	12.42 (4.56, 33.85)				•
Total events	42		14							
Heterogeneity: $tau^2 = 0$	$0.00; chi^2 = 0.$	11, $df = 2$	$(p = 0.95); I^2$	= 0%						
Test for overall effect: 2	$Z = 4.92 \ (p < p)$	0.00001)								
15.1.2 Chemotherapy c	ycles ≤ 3									
Fu L 2007	15	44	13	44	38.1	1.23 (0.50, 3.03)				
Liu ZZ 2005	5	50	5	50	18.0	1.00 (0.27, 3.69)				
Wang J 2016	19	21	15	21	10.2	3.80 (0.67, 21.60)		-		
Yang L 2004	17	31	8	28	26.2	3.04 (1.03, 8.96)				
Yang WJ 2005	2	30	2	30	7.5	1.00 (0.13, 7.60)				
Subtotal (95% CI)		176		173	100.0	1.66 (0.95, 2.89)			•	
Total events	58		43							
Heterogeneity: $tau^2 = 0$	$0.00; chi^2 = 3.$	31, $df = 4$	$(p = 0.51); I^2$	= 0%						
Test for overall effect: 2	Z = 1.79 (p = 1.79)	0.07)								
Test for subgroup differ	rences: chi ² =	11.84, df	= 1 (p = 0.00)	$(06); I^2 =$	91.6%					
0 1			Y			(0.001	0.1	1 10	1000
								Favours (control)	Favours (e	experimental)

FIGURE 7: Forest plot of performance status in subgroup analysis regarding chemotherapy cycles.

Study or subgroup	Experin Events	mental Total	Contr Events	ol Total	Weight (%)	Odds ratio M-H, random, 95% CI	Odds M-H, rando	ratio om, 95% CI	
3.1.1 Aidi low dose									
Fu L 2007	15	44	13	44	48.5	1.23 (0.50, 3.03)		-	
Yang L 2004	17	31	8	28	33.7	3.04 (1.03, 8.96)			
Wang J 2016	19	21	15	21	13.3	3.80 (0.67, 21.60)	_		
Wang GD 2012a	3	38	0	41	4.5	8.18 (0.41, 163.85)			_
Subtotal (95% CI)		134		134	100.0	2.11 (1.12, 3.99)		•	
Total events	54		36					•	
Heterogeneity: $tau^2 = 0.0$	01; $chi^2 = 3$.	04, $df = 3$	$(p = 0.38); I^2 =$	= 1%					
Test for overall effect: Z	= 2.30 (<i>p</i> =	0.02)	1						
3.1.2 Aidi high dose									
Liu ZZ 2005	5	50	5	50	29.5	1.00 (0.27, 3.69)		<u> </u>	
Yang WJ 2005	2	30	2	30	23.1	1.00 (0.13, 7.60)			
Chen WM 2016	34	39	14	40	30.9	12.63 (4.03, 39.55)			
Wang GD 2012b	5	32	0	41	16.5	16.60 (0.88, 312.40)	-		
Subtotal (95% CI)		151		161	100.0	3.48 (0.70, 17.36)	-		
Total events	46		21						
Heterogeneity: $tau^2 = 1.8$	84; $chi^2 = 10$	0.94, df = 3	$b (p = 0.01); I^2$	= 73%					
Test for overall effect: Z	= 1.52 (<i>p</i> =	0.13)	A),						
Test for subgroup differe	ences: chi ² =	0.32, df=	= 1 (p = 0.57);	$I^2 = 0\%$		Г			
0 1		- 5	4 /			0.00	0.1	10	1000
							Favours (control)	Favours (experin	mental)

FIGURE 8: Forest plot of performance status in subgroup analysis regarding Aidi injection high or low dose.

Study or subgroup	Experi Events	mental Total	Con Events	itrol Total	Weight (%)	Odds ratio M-H, random, 95%	CI	Odds ra M-H, randon	atio 1, 95% CI	
Chen WM 2016	8	39	18	40	24.8	0.32 (0.12, 0.85)				
Chen ZR 2012	28	30	25	26	4.1	0.56 (0.05, 6.56)				
Gao QH 2013a	25	32	32	32	2.9	0.05 (0.00, 0.96)				
Han YH 2014	15	64	32	64	42.8	0.31 (0.14, 0.65)				
Lu CH 2012	16	24	24	28	13.4	0.33 (0.09, 1.29)				
Shen SD 2013	25	26	22	22	2.3	0.38 (0.01, 9.75)				
Yang L 2004	27	31	25	28	9.7	0.81 (0.16, 3.98)				
Total (95% CI)		246		240	100.0	0.34 (0.20, 0.55)		•		
Total events	144		178							
Heterogeneity: $tau^2 = 0.00$; $chi^2 = 3.03$, $df = 6$ ($p = 0.80$); h				$I^2 = 0\%$						
Test for overall effect: 2	Z = 4.32 (p < 1)	0.0001)					0.001	0.1 1	10	1000
	<u>-</u> 4						F	avours (experimental)	Favours (contr	ol)

FIGURE 9: Forest plot of myelosuppression rate among patients receiving chemotherapy alone and chemotherapy plus Aidi injection.

TABLE 2: Summary of comparisons of ADRs among the patients receiving chemotherapy alone and chemotherapy plus Aidi injection.

ADRs	Number of studies	Number of patients	Heterogeneity (p/I^2)	Model	OR	p
Myelosuppression	7	486	0.80/0%	Fixed	0.34 [0.200, 55]	< 0.0001
III-IV myelosuppression	4	259	0.25/28%	Fixed	0.43 [0.25, 0.76]	0.003
Digestive tract reaction	8	623	0.72/0%	Fixed	0.50 [0.33, 0.76]	0.001
III-IV digestive tract reaction	4	269	0.06/59%	Random	0.42 [0.22, 0.80]	0.008
Liver dysfunction	5	432	0.80/0%	Fixed	0.90 [0.48, 1.68]	0.74
III-IV liver dysfunction	1	96	NA	NA	0.48 [0.08, 2.74]	0.41
Leukocyte decrease	3	152	0.41/0%	Fixed	0.43 [0.19, 0.97]	0.04
III-IV leukocyte decrease	4	313	0.03/67%	Random	0.40 [0.24, 0.66]	0.0003
Hair loss	1	88	NA	NA	0.78 [0.30, 2.07]	0.62
III-IV hair loss	1	96	NA	NA	0.71 [0.23, 2.24]	0.56
Phlebitis	2	132	0.61/0%	Fixed	0.89 [0.40, 1.96]	0.77
II-IV cardiac function abnormality	4	320	0.78/0%	Fixed	0.16 [0.13, 0.38]	< 0.00001
Atrial dysrhythmia	3	272	0.56/0%	Fixed	0.24 [0.13, 0.45]	< 0.00001
Ventricular arrhythmia	3	272	0.96/0%	Fixed	0.08 [0.01, 0.42]	0.003
Atrioventricular block	3	272	0.94/0%	Fixed	0.29 [0.05, 1.80]	0.18
ST segment T wave inversion	3	272	0.91/0%	Fixed	0.25 [0.15, 0.42]	< 0.00001
Abnormal ECG	3	272	0.80/0%	Fixed	0.17 [0.06, 0.47]	< 0.00001

NA = not applicable; ADRs = adverse drug reactions; OR = odds ratio; ECG = electrocardiogram.

Study or subgroup	Experin Events	mental Total	Con Events	itrol Total	Weight (%)	Odds ratio M-H, fixed, 95% C	I	Odds M-H, fixe	s ratio ed, 95% CI	
Chen WM 2016	2	39	7	40	10.4	0.25 (0.05, 1.31)			_	
Dang XG 2010	23	28	19	20	6.3	0.24 (0.03, 2.25)				
Fu L 2007	31	44	32	44	15.1	0.89 (0.35, 2.26)				
Han YH 2014	3	64	9	64	13.7	0.30 (0.08, 1.17)		_	_	
Li XQ 2006	27	32	19	20	5.8	0.28 (0.03, 2.63)				
Song WG 2006	13	48	16	48	18.6	0.74 (0.31, 1.78)				
Yang L 2004	19	31	23	28	14.9	0.34 (0.10, 1.15)			-	
Zhang J 2016	7	36	12	37	15.2	0.50 (0.17, 1.47)				
Total (95% CI)	322		301	100.0	0.50 (0.33, 0.76)		•			
Total events	125		137					•		
Heterogeneity: $chi^2 = 4.51$, $df = 7$ ($p = 0.72$); $I^2 =$			$^{2} = 0\%$							
Test for overall effect: 2	Z = 3.21 (p =	0.001)					0.01	0.1	1 10	100
								Favours (experimental)	Favours (control)	

FIGURE 10: Forest plot of digestive tract reaction rate among patients.

4. Discussion

Side effects in the treatment of breast cancer seriously affect the quality of life of patients and make development of alternative treatment necessary. In hospital of China, Chinese Patent Medicine Aidi injection was widely used as adjuvant drug in chemotherapy for breast cancer. We performed this meta-analysis to compare the efficacy and safety of Aidi injection plus chemotherapy and chemotherapy alone in treatment of breast cancer.

Our analysis demonstrated that addition of Aidi to chemotherapy significantly improved response rate and performance status improvement rate; Aidi plus chemotherapy group significantly decreased the rate of all grade and III-IV grade myelosuppression, the rate of all grade and III-IV grade digestive tract reaction, the rate of all grade and III-IV grade leukocyte decrease, and the rate of most of cardiac toxicity related adverse events. In regards of the other adverse drug reactions, the ADR rate was slightly reduced in Aidi plus chemotherapy group but showed no significance.

The heterogeneity in the analysis for response rate, myelosuppression rate, and digestive tract reaction rate was not significant but was significant in the analysis for performance status improvement rate. In order to identify source of heterogeneity, we made subgroup analysis according to chemotherapy cycle number and Aidi of high or low dosage, respectively. The subgroup analysis demonstrated that the chemotherapy cycle number, namely, the treatment duration of Aidi, was a source of heterogeneity, since the difference between two subgroup analyses was significant. We speculate that TCM usually takes a longer action time; on the other hand, longer Aidi usage may increase its effect compared with shorter usage. The two aspects together might explain the increased KPS improvement rate in subgroup with chemotherapy cycle number ≥ 3 .

The high dose Aidi might increase the KPS improvement rate since OR in high-dose subgroup analysis was higher than OR in low-dose subgroup analysis, but the difference between the high-dose and low-dose subgroup was not significant. Therefore, the dosage of Aidi might not be the source of heterogeneity in the total analysis for KPS improvement rate. We speculate that the high-dose and lowdose Aidi might not be very different regarding their effect on KPS, but it is also possible that the sample size is not large enough to identify their difference.

Chemotherapy is important treatment option for breast cancer for its clinical benefit, but it can also lead to side effects such as myelosuppression, digestive tract reactions, and cardiac toxicity. Its toxicity apparently affects patients that sometimes patients could not complete the whole chemotherapy cycle number. Our study demonstrated that addition of Aidi injection could significantly reduce the chemotherapy related toxicities, and Aidi injection itself did not show any obvious toxicity. The safe profile of Aidi injection had been validated by previous studies; for example, in the study by Hu et al., among the cancer patients who received Aidi injection in 2013-2015 in their department, the adverse drug reaction rate was about 1% [35]. Thus, we may conclude that Aidi injection has obvious toxicity-protection effect during chemotherapy treatment, which might partially explain the improved quality of life of patients, and the increased response rate since it may help patients to better complete chemotherapy courses.

Many studies explored the mechanism for activity of Aidi injection in cancer treatment. Aidi injection is prepared from Cantharidin, Ginsen, Astragaloside, and Acanthopanax senticosus. These Chinese herbal medicines have the ability to inhibit cancers and improve immunity as evidenced by a series of laboratory studies [36-39]. Cantharidin, as the central component in the whole preparation, is featured with anticancer activity and no concurrent myelosuppression [40, 41]. Experimental studies reported that cantharidin sodium injection is effective in the management of breast cancer [42], through inhibiting proliferation of breast cancer cells [43], suppressing authophage, and inducing apoptosis [44]. Aidi injection as the whole preparation has shown anticancer activity and ability of immunological function improvement [45]. For laboratory studies, it was reported that addition of Aidi injection to chemotherapy could significantly increase tumor inhibition rate and reduce Her-2/neu expression level in the nude mice breast carcinoma implanted of Her-2/neu over expression [46]; it could significantly inhibit cancer cell proliferation, induce cell apoptosis, and reduce cell diameter in the ErbB2 positive breast cancer cell BT-474, SK-BR-3, and HCC-1954 [47]; it significantly inhibited proliferation of MCF-9 cells in dose-dependent manner, accompanying altered expression profiles of microRNAs in MCF-9 cells [48]. For human studies, it was reported that Aidi injection treatment could reverse the suppression or promotion effect of chemotherapy on the peripheral blood level of CD3+, CD4+, CD8+, CD4+/CD8+, and NK cells [17, 22, 24, 26, 32, 33, 49]; Aidi injection plus chemotherapy decreased level of tumor markers CEA, CA153 more than chemotherapy alone [17]; addition of Aidi injection to chemotherapy could reduce serum VEGF level of breast cancer patients, that its anticancer action may be achieved through inhibition of tumor angiogenesis to inhibit proliferation, invasion, and metastasis of tumor cells [50].

Limitations. (1) Long-term efficacy is important measurement in breast cancer treatment, but the present study only evaluated short-term efficacy. The long-term efficacy measurements such as overall survival and 5-year survival rate were reported in a few included studies, but the measurements were different so pooled effect size could not be calculated. (2) Some included studies also evaluated the effect of addition of Aidi injection on the level of cardiac enzymes, liver function measurements, immune cells, and tumor markers, but those measurements could not be pooled in meta-analysis due to the presentation way of the results. (3) All studies were performed in China and published in Chinese journals, which may lead to certain bias. (4) The overall quality of the included studies was not high, and the blindness was not described by all the studies, so the results still shall be interpreted cautiously. (5) The adverse events were selectively reported in some included studies: for example, in some studies, multiple adverse events were recorded, but not each event was reported in standard with severity grades that the less common adverse events were roughly described with text, which may lead to reporting bias.

Finally, this is the second meta-analysis evaluated efficacy and safety of Aidi injection plus chemotherapy versus chemotherapy alone among breast cancer patients. Compared with the first published one, our analysis has included larger number of studies, thoroughly discussing adverse events of Aidi injections, and made subgroup analysis to identify the effect of treatment duration and dosage on KPS. According to our analysis, Aidi injection could increase the efficacy of chemotherapy and reduce myelosuppression, digestive tract reaction, and cardiac toxicity induced by chemotherapy and did not lead to additional toxicity and side effects. Therefore, it is an anticancer drug which might have good efficacy and low toxicity and worth further investigation.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest in this paper.

Authors' Contributions

C. Chen contributed to conceptualization. Q. Yongjun and Y. Chen contributed to data curation. H. Jinzhi and Z. Jun contributed to formal analysis. W. Chenhao and Q. Yongjun contributed to investigation. C. Chen contributed to supervision. H. Jinzhi and Y. Chen contributed to validation. H. Jinzhi, Z. Juan, and M. Min contributed to visualization. W. Chenhao wrote the original draft. W. Chenhao and M. Min contributed to review and editing.

References

- M. Akram, M. Iqbal, M. Daniyal, and A. U. Khan, "Awareness and current knowledge of breast cancer," *Biological Research*, vol. 50, no. 1, p. 33, 2017.
- [2] S.-J. Han, Q.-Q. Guo, T. Wang et al., "Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases," *Asian Pacific Journal of Cancer Prevention*, vol. 14, no. 10, pp. 6081–6084, 2013.
- [3] L. Yang, D. M. Parkin, J. Ferlay, L Li, and Y Chen, "Estimates of cancer incidence in China for 2000 and projections for 2005," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 14, no. 1, pp. 243–250, 2005.
- [4] H. Li, R. S. Zheng, S. W. Zhang et al., "Incidence and mortality of female breast cancer in China, 2014," *Zhonghua Zhong Liu Za Zhi*, vol. 40, no. 3, pp. 166–171, 2018.
- [5] J. Raphael and S. Verma, "Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome," *Breast Cancer Research and Treatment*, vol. 150, no. 3, pp. 473–478, 2015.
- [6] Y. Sun, "Experience and prospective of integrated medicine in treatment and prevention of cancer," *China Cancer*, vol. 2, pp. 436–438, 2003.
- [7] Chinese Pharmacopoepia Commission, *Pharmacopoeia of the People's Republic of China: Part I*, China Medical Science and Technology Press, Beijing, China, 2010.
- [8] Z. Y. An, Z. Wang, and Y. Zhao, "Anti-cancer research progress of cantharidin and its derivatives," Asia-Pacific Traditional Medicine, vol. 5, no. 1, pp. 128–130, 2009.
- [9] L. Liu, J. Liang, and X. Deng, "Effects of Aidi injection (艾迪 注射液) with western medical therapies on quality of life for patients with primary liver cancer: a systematic review and meta-analysis," *Chinese Journal of Integrative Medicine*, vol. 25, no. 10, pp. 785–790, 2019.
- [10] Z. Xiao, C. Wang, M. Zhou et al., "Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: a meta-analysis of 31 randomized controlled trials following the PRISMA guidelines," *Journal of Ethnopharmacology*, vol. 228, pp. 110–122, 2019.
- [11] W. Jiancheng, G. Long, Y. Zhao et al., "Effect of Aidi injection plus chemotherapy on gastric carcinoma: a meta-analysis of randomized controlled trials," *Journal of Traditional Chinese Medicine*, vol. 35, no. 4, pp. 361–374, 2015.
- [12] G. Li, P. J. Ye, X. J. Ying et al., "Clinical effect of Aidi injection combined with folfiri program in treatment of advanced

colorectal cancer," *Chinese Journal of General Practice*, vol. 13, pp. 1414–1416, 2015.

- [13] Y. S. Zhang, Q. Li, F. L. Sun, and L. Zhao, "Meta-analysis of Aidi injection treatment combining chop chemotherapy in treatment of malignant lymphoma," *Chinese Journal of New Drugs and Clinical Remedies*, vol. 33, pp. 807–812, 2014.
- [14] R. Z. Zhong, W. H. Xiao, J. Lin, and L. He, "Analysis of the clinical effects of Aidi injection combined with TC regimen on advanced epithelial ovarian cancer," *Anti-tumor Pharmacy*, vol. 5, pp. 366–369, 2014.
- [15] G. Xie, Z. H. Cui, K. Peng, X. H. Zhou, Q. Xia, and D. Xu, "Aidi injection, a traditional Chinese medicine injection, could be used as an adjuvant drug to improve quality of life of cancer patients receiving chemotherapy: a propensity score matching analysis," *Integrative Cancer Therapies*, vol. 18, Article ID 1534735418810799, 2019.
- [16] E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., "New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)," *European Journal of Cancer*, vol. 45, no. 2, pp. 228–247, 2009.
- [17] W. M. Chen, "Clinical observation of Aidi injection combined with CEF regimen for post-surgery patients with breast cancer," *Chinese Journal of Modern Drug Application*, vol. 10, pp. 185-186, 2016.
- [18] Z. R. Chen, S. D. Shen, and Z. Huang, "Effect of dose-dense AC→T regimen plus Aidi injection on triple-negative breast cancer," *Chinese Journal of Surgical*, vol. 4, no. 2, pp. 85–87, 2012.
- [19] X. G. Dang and L. Wang, "Evaluation of efficacy on breast cancer treated by Aidi injection plus CTF program of neoadjuvant chemotherapy and the impacts on serum sFas," *World Journal of Integrated Traditional and Western Medicine*, vol. 5, no. 1, pp. 54–56, 2010.
- [20] L. Fu and X. G. Kou, "Aidi injection combined with chemotherapy in treatment of 44 patients with advanced breast cancer," *Traditional Chinese Medicine*, vol. 23, no. 8, p. 517, 2007.
- [21] Q. H. Gao, "Clinical observation of Aidi combined with chemotherapy in treatment of metastatic breast cancer," *Chinese Journal of Modern Drug*, vol. 7, pp. 121-122, 2013.
- [22] Y. H. Han, X. Q. Jiang, H. Yang, Z. Y. Wu, and M. Jiang, "Clinical observation of Aidi injection combined with CEF regimen chemotherapy in treatment of postoperative breast cancer," *Hubei Journal of TCM*, vol. 36, pp. 7-8, 2014.
- [23] C. G. Jin, "Study of protective effect of supportive anti-cancer therapy for heart injury induced by post-surgery anthracycline chemotherapy for breast cancer," *Heilongjiang Medicine Journal*, vol. 29, pp. 270–272, 2016.
- [24] Z. Z. Liu, H. Liu, L. F. Li, and S. D. Cui, "Clinical observation of Aidi injection combined with chemotherapy in treatment of local advanced breast cancer," *Shandong Medical Journal*, vol. 45, no. 19, p. 62, 2005.
- [25] X. Q. Li and S. B. Gong, "Analysis of efficacy of Aidi injection combined with CEF regimen for breast cancer," *Pharmacology and Clinics of Chinese Materia Medica*, vol. 22, no. 3-4, pp. 176-177, 2006.
- [26] C. H. Lu, M. Hong, J. You et al., "Clinical Observation of Aidi injection combined with TAC regimen as post-surgery adjuvant chemotherapy for breast cancer," *Traditional Chinese Medicine Journal*, vol. 113, pp. 50–52, 2012.
- [27] Z. G. Ren and F. Zhang, "Efficacy observation on high dose of Aidi injection combined with chemotherapy in treatment of 60 patients with breast cancer," *Journal of Linyi Medical College*, vol. 27, no. 5, pp. 341–343, 2005.

- [28] S. D. Shen, Z. R. Chen, and G. F. Xiao, "Clinical observation of dose-dense TC→P regimen plus Aidi injection on triplenegative breast cancer," *Guide of China Medicine*, vol. 11, no. 8, pp. 84-85, 2013.
- [29] W. G. Song, Y. F. Wang, L. X. Yang et al., "Clinical observation of Aidi combined with chemotherapy in treatment of recurrent or metastatic breast cancer," *Chinese Journal of Cancer Prevention and Treatment*, vol. 13, no. 16, pp. 1275– 1280, 2006.
- [30] G. D. Wang, M. D. Lei, J. Y. Li et al., "Protective effect of compound cantharis injection on anthracycline chemotherapy induced cardiac injury in breast cancer patients," *China Pharmacy*, vol. 12, pp. 1100–1103, 2012.
- [31] J. Wang, "Efficacy of Aidi injection combined with chemotherapy in treatment of advanced breast cancer," *Yiyao Qianyan*, vol. 6, pp. 61-62, 2016.
- [32] L. Yang, "Clinical observation of Aidi injection combined with chemotherapy in treatment of advanced breast cancer," *Chinese Journal of Integrated Traditional and Western Medicine*, vol. 24, no. 8, pp. 755-756, 2004.
- [33] W. J. Yang, "Aidi injection combined with CAF regimen in treatment of 30 cases of advanced breast cancer," *Jiangxi Journal of Traditional Chinese Medicine*, vol. 36, no. 7, pp. 46-47, 2005.
- [34] J. Zhang, K. Xu, and S. L. Wang, "Randomized controlled trial of the supportive function of the Aidi injection in the process of chemotherapy in treating anthracycline-resistant metastatic breast cancer patients," *Guiding Journal of Traditional Chinese Medicine and Pharmacology*, vol. 22, pp. 27–30, 2016.
- [35] M. M. Hu, X. Q. Zhu, and M. Y. Zhu, "Analysis on application of traditional Chinese medicine injections in inpatients with tumor in Wenzhou People's Hospital during 2013-2015," *Evaluation and Analysis of Drug-Use in Hospitals of China*, vol. 16, pp. 1088–1090, 2016.
- [36] S. Ren, H. Zhang, Y. Mu, M. Sun, and P. Liu, "Pharmacological effects of Astragaloside IV: a literature review," *Journal* of *Traditional Chinese Medicine*, vol. 33, no. 3, pp. 413–416, 2013.
- [37] A. Ahuja, J. H. Kim, J.-H. Kim, Y.-S. Yi, and J. Y. Cho, "Functional role of ginseng-derived compounds in cancer," *Journal of Ginseng Research*, vol. 42, no. 3, pp. 248–254, 2018.
- [38] J. X. Du, Y. H. Gu, B. Zhang, and X. H. Zhu, "Research and evaluation on the antitumor effect of the active components from acanthopanax," *Evaluation and Analysis of Drug-Use in Hospitals of China*, vol. 10, pp. 199-200, 2010.
- [39] R. Rauh, S. Kahl, H. Boechzeh, R. Bauer, B. Kaina, and T. Efferth, "Molecular biology of cantharidin in cancer cells," *Chinese Medicine*, vol. 2, pp. 8–16, 2007.
- [40] J. M. Chang and Y. Q. Zhang, "Analysis of the factors affecting efficacy and toxicity of cantharidin," *Clinical Journal of Chinese Medicine*, vol. 4, no. 4, pp. 67-68, 2012.
- [41] K. Bonness, I. V. Aragon, R. Beth, N. M. Dean, and R. E. Honkanen, "Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aα," *Molecular Cancer Therapeutics*, vol. 5, no. 11, pp. 2727–2736, 2006.
- [42] S. Huang and K. Cao, "Anti-invasive and anti-metastasis effect of norcantharidin on high-metastatic human breast cancer cell lines," *Journal of Tropical Medicine*, vol. 9, pp. 1034–1045, 2010.
- [43] J. Y. Wang, J. L. Liang, and G. J. Liu, "Effect of Norcantharidin on expression of VEGF mRNA in human breast cancer cell

lines," Chinese Archives of Traditional Chinese Medicine, vol. 27, no. 11, pp. 2369–2371, 2009.

- [44] H.-C. Li, Z.-H. Xia, Y.-F. Chen et al., "Cantharidin inhibits the growth of triple-negative breast cancer cells by suppressing autophagy and inducing apoptosis in vitro and in vivo," *Cellular Physiology and Biochemistry*, vol. 43, no. 5, pp. 1829–1840, 2017.
- [45] J. Xu, W. Z. Ju, and H. S. Tan, "Summary of studies investigating action mechanisms and clinical application of Aidi injection," *Pharmaceutical and Clinical Research*, vol. 20, no. 1, pp. 48–51, 2012.
- [46] X. M. Zhang, X. Liu, and Q. Pan, "Effects of chemotherapy and Aidi injection on nude mice breast carcinoma implanted of Her-2/neu over-expression," *Journal of Emgergency of Traditional Chinese Medicine*, vol. 18, pp. 1654–1657, 2009.
- [47] J. Tang and G. J. Wang, "Antitumor effect of Aidi injection on ErbB2-positive breast cancer cells and mechanisms of action," *Journal of Chinese Pharmaceutical Sciences*, vol. 34, pp. 333–340, 2018.
- [48] H. Zhang, Q.-M. Zhou, Y.-Y. Lu, J. Du, and S.-B. Su, "Aidi injection () alters the expression profiles of MicroRNAs in human breast cancer cells," *Journal of Traditional Chinese Medicine*, vol. 31, no. 1, pp. 10–16, 2011.
- [49] L. W. Chu, Z. Y. Wen, L. G. Zhang, Y. Z. Pei, and W. L. Gong, "Analysis of effect of Aidi injection on cellular immunology of breast cancer patients," *China Medical Engineering*, vol. 21, pp. 36-37, 2013.
- [50] M. Wang and L. Wu, "Effect of Aidi injection on serum VEGF in patients with breast cancer," *Chinese Journal of Clinical Research*, vol. 26, pp. 1151–1158, 2013.